TG Therapeutics (TGTX) Stock Forecast & Price Target

TG Therapeutics is expected to see growth in its market share with the initiation of its Phase 2 trial for Briumvi in treatment-resistant schizophrenia, presenting a high-risk/high-reward opportunity. Data from the ongoing Phase 4 ENABLE study also highlights the convenience and satisfaction of Briumvi, reinforced by its differentiated single infusion regimen that should further accelerate anti-CD20 switches. Insurance and infusion centers are becoming the primary drivers in anti-CD20 selection, and the single infusion initiation of Briumvi will likely drive incremental market share gains and support continued growth in the biotech sector.

TG Therapeutics is facing significant competition in the oral BTK inhibitor class, with positive data from fenebrutinib and a superior safety profile compared to other BTK inhibitors. However, its dosing schedule and potential compliance concerns may limit its success in the market, particularly against highly effective B-cell depleting therapies. Their current valuation and price target are based on discounted cash flow analysis, with risks including safety signals, lower efficacy, commercial competition, regulatory concerns, and patent protection.